Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norihiro Hayashi

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Pathology International|November 6, 2012
Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patientsTakahiro Kimura, Bungo Furusato, Jun Miki, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 17, 2015
Oxidized LDL (oxLDL) activates the angiotensin II type 1 receptor by binding to the lectin-like oxLDL receptorKoichi Yamamoto, Akemi Kakino, Hikari Takeshita, et al.
EMBO Molecular Medicine|January 20, 2018
SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1James W Peacock, Ario Takeuchi, Norihiro Hayashi, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Pathology International|November 6, 2012
Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patientsTakahiro Kimura, Bungo Furusato, Jun Miki, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 17, 2015
Oxidized LDL (oxLDL) activates the angiotensin II type 1 receptor by binding to the lectin-like oxLDL receptorKoichi Yamamoto, Akemi Kakino, Hikari Takeshita, et al.
EMBO Molecular Medicine|January 20, 2018
SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1James W Peacock, Ario Takeuchi, Norihiro Hayashi, et al.
Pageof 4